Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
Dose-Dependent efficacy and safety of Brexpiprazole in agitation associated with dementia in Alzheimer's disease: A systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Javaid Hammad, Jha Anurag, Cheema Umaima, Noor Meeram, Cheema Shamikha, Arfan Mahnoor, Aqeel Maryyam, Habib Erum, Saddique Muhammad Nabeel, Qadri Maria, Shamoon Sheena
Аннотация
BACKGROUND: Agitation is one of the most distressing neuropsychiatric symptoms in patients with dementia due to Alzheimer's disease (AD), significantly impacting patients' quality of life and increasing caregiver burden. Brexpiprazole, a serotonin-dopamine modulator, shows promise for managing agitation. This meta-analysis evaluates the efficacy and safety in managing agitation associated AD.
METHOD: A comprehensive literature search was conducted across PubMed, Cochrane, Scopus, Embase and ClinicalTrials.gov from inception until January 2025. We pooled dichotomous outcomes as risk ratios (RR) and continuous outcomes as mean differences (MD) with 95% confidence intervals (CI), using random-effects models. Heterogeneity was assessed using I² and X² statistics. A p-value of < 0.05 was considered statistically significant. All the calculations were performed using RevMan 5.4.
RESULT: This meta-analysis included 4 studies involving 1440 patients (944 vs. 496) suffering from agitation associated with dementia in AD. Brexpiprazole significantly reduced agitation on CMAI (MD: -3.94 [-6.21 to -1.67], p < 0.001) and NPI-NH (MD: -0.67 [-1.08 to -0.26], p = 0.002) with optimal efficacy at 2-3 mg/day. SAS scores worsened slightly (MD: 0.38 [0.18-0.58], p = 0.0002) while MMSE (p = 0.06) and CGI-S (p = 0.06) remained stable. No significant differences emerged in serious adverse events, mortality, dizziness, or extrapyramidal effects (all p > 0.05).
CONCLUSION: Brexpiprazole effectively reduces agitation in AD without major safety concerns, though mild motor effects were noted. Study limitations include moderate heterogeneity and short trial durations. Future research should explore long-term outcomes and patient stratification.
METHOD: A comprehensive literature search was conducted across PubMed, Cochrane, Scopus, Embase and ClinicalTrials.gov from inception until January 2025. We pooled dichotomous outcomes as risk ratios (RR) and continuous outcomes as mean differences (MD) with 95% confidence intervals (CI), using random-effects models. Heterogeneity was assessed using I² and X² statistics. A p-value of < 0.05 was considered statistically significant. All the calculations were performed using RevMan 5.4.
RESULT: This meta-analysis included 4 studies involving 1440 patients (944 vs. 496) suffering from agitation associated with dementia in AD. Brexpiprazole significantly reduced agitation on CMAI (MD: -3.94 [-6.21 to -1.67], p < 0.001) and NPI-NH (MD: -0.67 [-1.08 to -0.26], p = 0.002) with optimal efficacy at 2-3 mg/day. SAS scores worsened slightly (MD: 0.38 [0.18-0.58], p = 0.0002) while MMSE (p = 0.06) and CGI-S (p = 0.06) remained stable. No significant differences emerged in serious adverse events, mortality, dizziness, or extrapyramidal effects (all p > 0.05).
CONCLUSION: Brexpiprazole effectively reduces agitation in AD without major safety concerns, though mild motor effects were noted. Study limitations include moderate heterogeneity and short trial durations. Future research should explore long-term outcomes and patient stratification.